嚢胞性線維症治療の世界市場2020-2042

◆英語タイトル:GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028
◆商品コード:INK20MY031
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年3月
◆ページ数:176
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは嚢胞性線維症治療の世界市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、投与経路別(吸入、経口)分析、薬種別(CFTRモジュレーター、気管支拡張薬、粘液活性剤、膵酵素サプリメント)分析、地域別分析、企業情報などの情報をお届けいたします。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・嚢胞性線維症治療世界市場:投与経路別(吸入、経口)
・嚢胞性線維症治療世界市場:薬種別(CFTRモジュレーター、気管支拡張薬、粘液活性剤、膵酵素サプリメント)
・地域別分析
・企業情報
【レポートの概要】

KEY FINDINGS
The global cystic fibrosis therapeutics market is anticipated to grow at a rate of 10.04% during the estimated period of 2020-2028. A rise in incidences of cystic fibrosis across the globe, an increase in medications against cystic fibrosis, and a hike in R&D investments towards the development of drugs to treat cystic fibrosis are boosting the market.

MARKET INSIGHTS
Cystic fibrosis is a disease that is inherited and mainly affects the lungs and other body parts like the kidney, pancreas, and liver. In cystic fibrosis, thick and sticky mucus is produced by the body that may block the lungs and obstruct the pancreas. There is no cure for the fatal disease, but taking proper medication and nutrition to reduce excess mucus produced in the lungs and kidney can help in increasing the patient’s lifespan. The disease is most prevalent in newborns, and has led the researchers towards the development of advanced therapeutics, which may increase the life span of the patients. However, the high costs involved in cystic fibrosis treatment and the introduction of generic drugs impede the market growth. At the same time, the growth of the healthcare industry in developing economies is expected to create profitable opportunities in the future.

REGIONAL INSIGHTS
The global cystic fibrosis therapeutics market is geographically analyzed based on markets situated in North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of Europe holds the largest market share in terms of revenue, and continues the trend by the end of the forecast period. This is attributed to the presence of key players investing largely in the development of new technologies. The market region of Europe is predicted to be the fastest-growing market in terms of revenue. The major factor driving the growth is the surge in incidences of cystic fibrosis in the region.

COMPETITIVE INSIGHTS
Abbott Laboratories, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Pharmaxis Ltd, Novartis International AG, etc. are some of the leading companies registering their presence in the global market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
3.3. KEY RESTRAINTS
3.3.1. STRINGENT REGULATION
3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. PESTEL ANALYSIS
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY ROUTE OF ADMINISTRATION
5.1. INHALE
5.2. ORAL
6. MARKET BY DRUG CLASS
6.1. CFTR MODULATORS
6.2. BRONCHODILATORS
6.3. MUCOLYTIC
6.4. PANCREATIC ENZYME SUPPLEMENTS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. ITALY
7.2.5. RUSSIA
7.2.6. BELGIUM
7.2.7. POLAND
7.2.8. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. JAPAN
7.3.3. INDIA
7.3.4. AUSTRALIA & NEW ZEALAND
7.3.5. SOUTH KOREA
7.3.6. THAILAND
7.3.7. INDONESIA
7.3.8. VIETNAM
7.3.9. REST OF ASIA PACIFIC
7.4. REST OF WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST & AFRICA
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ABBVIE INC
8.3. AGILENT TECHNOLOGIES INC
8.4. ALLERGAN PLC
8.5. F. HOFFMANN-LA ROCHE
8.6. GILEAD SCIENCES INC
8.7. GLAXOSMITHKLINE PLC
8.8. JOHNSON & JOHNSON
8.9. MYLAN N.V
8.10. NOVARTIS AG
8.11. PERKINELMER
8.12. PFIZER INC
8.13. PHARMAXIS LTD
8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
8.15. VERTEX PHARMACEUTICALS INCORPORATED



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[嚢胞性線維症治療の世界市場2020-2042]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆